Shopping Cart 0
Cart Subtotal
USD 0

BiondVax Pharmaceuticals Ltd (BVXV) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

BiondVax Pharmaceuticals Ltd (BiondVax) is a biopharmaceutical company that develops universal flu vaccine. The company's lead product M-001 is a synthetic peptide-based protein that provides protection against human influenza virus strains including seasonal influenza strains; and pandemic influenza strains such as swine flu and avian flu. Its vaccine helps to provide multi-strain, multi season and long-term protection against various flu viruses. The company uses synthetic peptides in vaccines which offers practical advantages such as relative ease of production, chemical stability, and an avoidance of any infectious or oncogenic potential hazard. BiondVax is headquartered in Ness Ziona, Israel.

BiondVax Pharmaceuticals Ltd (BVXV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

BiondVax Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 11

Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 12

Equity Offering 14

BiondVax Pharma Raises USD10 Million in Public Offering of American Depositary Shares 14

BiondVax Pharma Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of American Depositary Shares for USD10.12 Million 16

BiondVax Pharma Announces Public Offering Of Units For USD 1.3 Million 18

Acquisition 19

Angels High Tech Investments Acquires 19.99% stake in BiondVax Pharma for USD2.8 Million 19

BiondVax Pharmaceuticals Ltd-Key Competitors 20

BiondVax Pharmaceuticals Ltd-Key Employees 21

BiondVax Pharmaceuticals Ltd-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Aug 22, 2018: BiondVax Pharmaceuticals reports second quarter 2018 financial results 23

May 29, 2018: BiondVax Announces First Quarter 2018 Financial Results 24

Apr 30, 2018: BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update 25

Nov 28, 2017: BiondVax Provides Third Quarter 2017 Financial Results and Update 26

Aug 31, 2017: BiondVax Provides Second Quarter 2017 Financial Results and Update 27

May 30, 2017: BiondVax Announces First Quarter 2017 Financial Results and Update 28

Apr 28, 2017: BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update 29

Corporate Communications 30

Jun 28, 2018: Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors 30

Aug 31, 2017: Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange 31

Other Significant Developments 32

Jun 28, 2017: BiondVax's CEO Provides First Half 2017 General Corporate Update 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

BiondVax Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BiondVax Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

BiondVax Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 11

Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 12

BiondVax Pharma Raises USD10 Million in Public Offering of American Depositary Shares 14

BiondVax Pharma Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of American Depositary Shares for USD10.12 Million 16

BiondVax Pharma Announces Public Offering Of Units For USD 1.3 Million 18

Angels High Tech Investments Acquires 19.99% stake in BiondVax Pharma for USD2.8 Million 19

BiondVax Pharmaceuticals Ltd, Key Competitors 20

BiondVax Pharmaceuticals Ltd, Key Employees 21

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

BiondVax Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

BiondVax Pharmaceuticals Ltd (BiondVax) is a biopharmaceutical company that develops universal flu vaccine. The company's lead product M-001 is a synthetic peptide-based protein that provides protection against human influenza virus strains including seasonal influenza strains; and pandemic influenza strains such as swine flu and avian flu. Its vaccine helps to provide multi-strain, multi season and long-term protection against various flu viruses. The company uses synthetic peptides in vaccines which offers practical advantages such as relative ease of production, chemical stability, and an avoidance of any infectious or oncogenic potential hazard. BiondVax is headquartered in Ness Ziona, Israel.

BiondVax Pharmaceuticals Ltd (BVXV)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

BiondVax Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 11

Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 12

Equity Offering 14

BiondVax Pharma Raises USD10 Million in Public Offering of American Depositary Shares 14

BiondVax Pharma Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of American Depositary Shares for USD10.12 Million 16

BiondVax Pharma Announces Public Offering Of Units For USD 1.3 Million 18

Acquisition 19

Angels High Tech Investments Acquires 19.99% stake in BiondVax Pharma for USD2.8 Million 19

BiondVax Pharmaceuticals Ltd-Key Competitors 20

BiondVax Pharmaceuticals Ltd-Key Employees 21

BiondVax Pharmaceuticals Ltd-Locations And Subsidiaries 22

Head Office 22

Recent Developments 23

Financial Announcements 23

Aug 22, 2018: BiondVax Pharmaceuticals reports second quarter 2018 financial results 23

May 29, 2018: BiondVax Announces First Quarter 2018 Financial Results 24

Apr 30, 2018: BiondVax Announces Fourth Quarter and Full Year 2017 Financial Results and Update 25

Nov 28, 2017: BiondVax Provides Third Quarter 2017 Financial Results and Update 26

Aug 31, 2017: BiondVax Provides Second Quarter 2017 Financial Results and Update 27

May 30, 2017: BiondVax Announces First Quarter 2017 Financial Results and Update 28

Apr 28, 2017: BiondVax Announces Fourth Quarter and Full Year 2016 Financial Results and Update 29

Corporate Communications 30

Jun 28, 2018: Corporate Biotech Executive Mark Germain Joins BiondVax's Board of Directors 30

Aug 31, 2017: Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange 31

Other Significant Developments 32

Jun 28, 2017: BiondVax's CEO Provides First Half 2017 General Corporate Update 32

Appendix 33

Methodology 33

About GlobalData 33

Contact Us 33

Disclaimer 33


List Of Figure

List of Figures

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

BiondVax Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9


List Of Table

List of Tables

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

BiondVax Pharmaceuticals Ltd, Deals By Therapy Area, 2012 to YTD 2018 8

BiondVax Pharmaceuticals Ltd, Medical Devices Deals, 2012 to YTD 2018 9

BiondVax Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

BiondVax Pharma Enters into Agreement with National Institute of Allergy and Infectious Diseases 11

Monosol Enters Into Agreement With BiondVax To Develop Oral Delivery For Flu Vaccine 12

BiondVax Pharma Raises USD10 Million in Public Offering of American Depositary Shares 14

BiondVax Pharma Completes Partial Exercise of Underwriter's Over Allotment Option for Public Offering of American Depositary Shares for USD10.12 Million 16

BiondVax Pharma Announces Public Offering Of Units For USD 1.3 Million 18

Angels High Tech Investments Acquires 19.99% stake in BiondVax Pharma for USD2.8 Million 19

BiondVax Pharmaceuticals Ltd, Key Competitors 20

BiondVax Pharmaceuticals Ltd, Key Employees 21

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

BiondVax Pharmaceuticals Ltd, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.